September 10, 2025Frontiers in PharmacologyOpen Access

Baicalein ameliorates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and regulating gut microbiota

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis showed baicalein improves ulcerative colitis by reducing inflammation and modulating gut microbiota.

Baicalein significantly improves ulcerative colitis symptoms, particularly at higher doses, reducing inflammation.
Key findings indicate that baicalein lowers pro-inflammatory cytokines like TNF-α and IL-1β while increasing IL-10.
The study used a DSS-induced murine model to assess protective effects against ulcerative colitis effectively.
These results highlight baicalein's potential as a novel treatment option for ulcerative colitis, warranting further exploration.

Lv et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 10, 2025Frontiers in PharmacologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis showed baicalein improves ulcerative colitis by reducing inflammation and modulating gut microbiota.

Baicalein significantly improves ulcerative colitis symptoms, particularly at higher doses, reducing inflammation.
Key findings indicate that baicalein lowers pro-inflammatory cytokines like TNF-α and IL-1β while increasing IL-10.
The study used a DSS-induced murine model to assess protective effects against ulcerative colitis effectively.
These results highlight baicalein's potential as a novel treatment option for ulcerative colitis, warranting further exploration.

Lv et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark